These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 18473286

  • 1. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
    Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG.
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):600-5. PubMed ID: 18473286
    [Abstract] [Full Text] [Related]

  • 2. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
    Haupt E, Ledermann H, Köpcke W.
    Int J Clin Pharmacol Ther; 2005 Feb; 43(2):71-7. PubMed ID: 15726875
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
    Stirban A, Pop A, Tschoepe D.
    Diabet Med; 2013 Oct; 30(10):1204-8. PubMed ID: 23701274
    [Abstract] [Full Text] [Related]

  • 4. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients.
    Hahm JR, Kim BJ, Kim KW.
    J Diabetes Complications; 2004 Oct; 18(2):79-85. PubMed ID: 15120701
    [Abstract] [Full Text] [Related]

  • 5. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
    Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R.
    Diabetes Care; 2006 Nov; 29(11):2365-70. PubMed ID: 17065669
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
    Ekberg K, Brismar T, Johansson BL, Lindström P, Juntti-Berggren L, Norrby A, Berne C, Arnqvist HJ, Bolinder J, Wahren J.
    Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P, Le Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, LeFante C.
    J Diabetes Complications; 2005 Jan; 19(5):247-53. PubMed ID: 16112498
    [Abstract] [Full Text] [Related]

  • 11. [Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients].
    MMW Fortschr Med; 2004 Jan 29; 146(5):52-3. PubMed ID: 15035429
    [No Abstract] [Full Text] [Related]

  • 12. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
    Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, Chappell AS.
    Diabetes Care; 2007 Mar 29; 30(3):664-9. PubMed ID: 17327338
    [Abstract] [Full Text] [Related]

  • 13. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study.
    Atli A, Dogra S.
    Pain Med; 2005 Mar 29; 6(3):225-34. PubMed ID: 15972086
    [Abstract] [Full Text] [Related]

  • 14. [Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs].
    Bregovskiĭ VB, Posokhina OV, Karpova IA.
    Ter Arkh; 2005 Mar 29; 77(10):15-9. PubMed ID: 16320678
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
    Bönhof GJ, Sipola G, Strom A, Herder C, Strassburger K, Knebel B, Reule C, Wollmann JC, Icks A, Al-Hasani H, Roden M, Kuss O, Ziegler D.
    BMJ Open; 2022 Feb 03; 12(2):e057142. PubMed ID: 35115359
    [Abstract] [Full Text] [Related]

  • 17. Benfotiamine relieves inflammatory and neuropathic pain in rats.
    Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI, Vidal-Cantú GC, Medina-Santillán R, Reyes-García G, Granados-Soto V.
    Eur J Pharmacol; 2006 Jan 13; 530(1-2):48-53. PubMed ID: 16359659
    [Abstract] [Full Text] [Related]

  • 18. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device.
    Forst T, Nguyen M, Forst S, Disselhoff B, Pohlmann T, Pfützner A.
    Diabetes Nutr Metab; 2004 Jun 13; 17(3):163-8. PubMed ID: 15334794
    [Abstract] [Full Text] [Related]

  • 19. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus.
    Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME.
    J Diabetes Complications; 2008 Jun 13; 22(4):241-5. PubMed ID: 18413214
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 13; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.